Key facts
- Eva Medtec’s last known valuation is $11.1M (Mar 2023).
- It has raised $2.5M across 1 recorded rounds; the latest was Seed Round ($480K) in Aug 2019.
- Eva Medtec has filed 9 Form Ds with the SEC since 2015, most recently May 2025 ($50K sold to 1 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 1 rounds
- ·Watchlist + deal alerts for Eva Medtec
Funding rounds
1 roundsAbout Eva Medtec
Developer of a medical device intended to offer lymphatic drainage therapy. The company's device can be used for many chronic conditions, such as arthritis, sports injuries, muscle tissue soreness and pain, headaches, neck pain, fibromyalgia, and joint pain, enabling patients to manage acute or chronic pain.
- Sector
- Healthcare
- HQ
- Shakopee, MN, United States
- Founded
- 2012
- Employees
- 4
- Website
- neuroglide.com/
- Ownership
- Privately Held (backing)
Eva Medtec doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Eva Medtec shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Eva Medtec in its N-PORT filings yet. We sweep new filings monthly.